East Region Formulary
NHS Scotland

Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Filter
Select filter(s)
Bimekizumab
Bimzelx
Routinely available
SMC ( SMC2616)
18/03/2026

Indication

Axial spondyloarthritis - For the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately or are intolerant to non-steroidal...

Axial spondyloarthritis - For the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs). - For the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Therapeutic Area

Musculoskeletal and joint diseases

Status Description

Routinely available in line with national guidance

Formulation

solution for injection in pre-filled syringe/prefilled pen

Comments

Link to Advice

SMC2616

Advice Published

11/12/2023

SMC Submission Type

Abbreviated

SMC Status

Accepted